GlassScriptPhysician profile
Seema K Doshi
NPI 1902882814
$7,448.32
in general payments reported to CMS, 2019-2025
34 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $901 · 2021: $993 · 2022: $872 · 2023: $1,195 · 2024: $1,227 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,337.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,282.66 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $775.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.84 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $349.25 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $308.61 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $294.18 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $259.60 | 2021-2025 | |
| Abbvie INC. | $223.47 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $218.53 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $217.36 | 2019-2021 | |
| Galderma Laboratories, L.P. | $211.58 | 2025 | Nemluvio, Aklief |
| Merck Sharp & Dohme LLC | $170.80 | 2019-2021 | |
| Dexcom, INC. | $140.52 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $133.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $132.90 | 2019-2023 | |
| Amarin Pharma, INC. | $96.32 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $86.49 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $81.80 | 2023-2024 | Azstarys |
| Xeris Pharmaceuticals, INC. | $75.87 | 2023-2025 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $72.10 | 2019-2023 | Jornay Pm |
| Neurelis, INC. | $70.39 | 2021-2024 | Valtoco |
| Abbott Laboratories | $63.34 | 2022-2024 | Freestyle Libre 3 |
| Allergan, INC. | $56.41 | 2020-2021 | |
| Tris Pharma INC | $32.16 | 2022-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $23.91 | 2019 | |
| Biomarin Pharmaceutical INC. | $22.04 | 2023 | Voxzogo 1.2mg |
| Axsome Therapeutics, INC. | $20.89 | 2025 | Auvelity |
| Tandem Diabetes Care, INC. | $18.15 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Mayne Pharma Commercial LLC | $18.05 | 2023 | |
| Almatica Pharma LLC | $17.73 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.03 | 2022 | |
| Grifols USA, LLC | $13.65 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.